4D Molecular Therapeutics Inc Phase 1/2 Clinical Trial of 4D-150 for Wet AMD - Corporate Call Transcript
Hello, ladies and gentlemen. Thank you for standing by, and welcome to 4D Molecular Therapeutics 4D-150 Phase I/II for Wet AMD Interim Clinical Data Conference Call. (Operator Instructions) As a reminder, today's call is being recorded.
With that, I will hand the call over to August Moretti, Chief Financial Officer, who will make introductory comments.
Thank you, operator, and welcome, everyone, to 4D Molecular Therapeutics' 4D-150 Phase I/II for Wet AMD Interim Clinical Data Conference Call. A press release describing the interim results from our Phase I/II clinical trial of 4D-150 in patients with wet AMD is accessible in the Investors section of the 4D Molecular Therapeutics website. And a recording of this webcast will be accessible on our website after completion of the call.
With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer; and Dr. Arshad Khanani, Managing Partner and Director of Clinical Research at Sierra Eye Associates and Clinical Associate
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |